Pharco Corporation is committed to continuous research and development to discover new solutions for today’s foremost medical challenges. This includes finding new uses for existing products and investigating entirely new areas of pharmaceutical science.  This commitment resulted in the discovery of Mirazid ®, the new era in the treatment of schistosomiasis and facioliasis. Mirazid ® is the first Egyptian product of its kind with patency from the USA, Japan and Europe. By 2007, Mirazid had 63% market share with 832,000 in sales.

Newly developed drugs go through a rigorous approval process consisting of three phases. Phase one is the animal toxicology and pharmacology phase. Once a drug passes through phase one, it goes to phase two for human clinical studies in small numbers of volunteers. Phase three involves comparative trials on large numbers of patients.

Pharco R&D group enjoys the synergy of its expert staff and is made up of 40 leading medical experts lead by a professor of Pharmaceuticals of Alexandria University. The group works in three state of the art research facilities; a Bioreactor lab, a chemical synthesis lab and a special lab for animal studies. Research activities are also outsourced to university facilities such as Science Park, a new modern research center donated to Alexandria University by Pharco Corporation. Pharco also collaborates with the National Research Institute on several research projects.